
Pharma stops building AI pipelines, buys Chai Discovery instead
Chai Discovery's shift from open-sourcing foundational models to closing enterprise deals with major pharma players reveals a critical inflection point in AI-driven drug discovery. The company's progression from Chai-1 through Chai-2 demonstrates how model accuracy improvements, particularly in structural prediction tasks like cryo-EM analysis, have crossed a trust threshold that pharma executives previously thought required in-house infrastructure. This represents a broader landscape shift where specialized AI tools are now commoditizing within regulated industries, forcing incumbents to buy rather than build, and signaling that domain-specific model maturity can unlock enterprise adoption faster than general-purpose AI.85










